Romiplostim Mechanism and Clinical Relevance

Pharmacodynamics and Efficacy

The American Society of Hematology notes that romiplostim has no structural similarity to endogenous TPO, which eliminates the theoretical risk of developing neutralizing anti-TPO antibodies that occurred with earlier recombinant TPO formulations 1
Platelet responses to romiplostim typically occur within 1-2 weeks of initiating treatment, with median time to response of approximately 2 weeks in clinical studies, as reported by the American Society of Hematology 2
The American Society of Hematology also reports that platelet responses to romiplostim typically occur within 1-2 weeks of initiating treatment, with median time to response of approximately 2 weeks in clinical studies, with a strength of evidence supported by multiple clinical studies 3

The American College of Hematology recommends romiplostim as it works by increasing platelet production rather than reducing immune-mediated destruction, making it a unique drug class that directly and specifically improves platelet counts through enhanced bone marrow production 1
Some evidence suggests romiplostim may have disease-modifying effects beyond simple platelet production, potentially through restoration of impaired regulatory T-cell function and immune tolerance, as noted by the American Society of Hematology, although this remains under investigation 1